Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansa Biopharma AB ( (SE:HNSA) ) has provided an announcement.
Hansa Biopharma has convened its Annual General Meeting for June 1, 2026, in Lund, outlining detailed procedures for shareholders to participate either in person or via advance voting. The notice clarifies eligibility requirements, proxy rules and nominee registration steps to ensure that both directly registered and nominee-registered shareholders can exercise their voting rights.
The agenda covers approval of the 2025 financial statements, discharge of board and CEO liability, determination of board and auditor numbers and fees, and the re-election of all current board members with Peter Nicklin proposed to continue as chair. Shareholders will also vote on auditor appointments, nomination committee principles, executive remuneration guidelines, and the introduction of a new long-term share-based incentive program (Board RSU 2026) for directors, signaling continued emphasis on governance and alignment with shareholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a Swedish biopharmaceutical company based in Lund, focused on developing and commercializing innovative immunomodulatory treatments. The company operates under a corporate governance framework that includes an active board and shareholder base, reflecting its status as a listed public company with formal annual general meeting procedures.
Average Trading Volume: 388,389
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK2.55B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.